Brought to you by 
Jomed NV invests in Pathway Medical and CardioPath
17 Sep 2002
Executive Summary
Jomed NV (IVUS and other MIS vascular interventional technology) has licensed exclusive rights in Europe, Japan, and other world markets outside the US, to Pathway Medical Technologies' CardioPath debulking system, a catheter-based drilling device that opens diseased and clogged arteries and bypass grafts, usually so stents can be placed.
Deal Industry
- Medical Devices
-
Medical Devices
- Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Jomed NV invests in Pathway Medical and CardioPath
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice